search.
PHYSIOLOGY AND PHARMACOLOGY OF VASOPRESSIN Endogenous Vasopressin
Arginine vasopressin is released from the posterior pituitary in response to increased serum osmolality or reduced plasma volume 1, 2 . Under normal conditions, the major physiological role of vasopressin is the regulation of water balance. It does not appear to play a major role in the vascular regulation of blood pressure and abnormally high endogenous vasopressin levels (syndrome of inappropriate antidiuretic hormone (ADH) secretion) do not produce hypertension 3 . In shock states however, endogenous vasopressin release is an important vasoconstrictor mechanism. In common with other stress hormones such as the catecholamines, hypotension stimulates vasopressin release via activation of aortic and carotid baroreceptors. Patients in cardiac arrest undergoing cardiopulmonary resuscitation (CPR) have very high levels of circulating vasopressin 4 (up to 469 pg/ml, normal <5 pg/ml 5 ). Plasma levels of vasopressin increase within a few minutes of circulatory arrest and also rise in response to haemorrhage 6 , sepsis 7, 8 , myocardial infarction 9, 10 , cardiopulmonary bypass (CPB) 11, 12 , epidural 13 and general anaesthesia 14 , surgery 15 and exercise 16 . However, prolonged hypovolaemia 17, 18 , sepsis 19 and CPB 20, 21 may lead to vasopressin levels that are inappropriately low for the given degree of hypotension. This may contribute to the development of pathologic vasodilatation that may occur during advanced shock. The mechanism by which relative vasopressin deficiency occurs is incompletely understood. One explanation is that exhaustion of secretory stores in the neurohypophysis and hypothalamus may occur after prolonged stimulation of vasopressin release. This has been shown to occur in response to other potent stimuli of vasopressin release such as severe hypernatraemia 22, 23 . Another possibility is that impaired autonomic function may reduce the baroreflex-mediated stimulation of vasopressin release 19, 20 . Primary autonomic failure has been shown to inhibit the baroreflex-mediated secretion of vasopressin 24, 25 and impaired autonomic function has also been shown to occur in septic shock 26 and following CPB 27, 28 .
Cardiovascular Actions of Exogenous Vasopressin
The vascular response to exogenous vasopressin is markedly enhanced by a variety of shock states. For example, doses of vasopressin that have minimal pressor action in normal subjects (~0.02 U/min) 29, 30 produce marked effects in sepsis 31 and haemorrhagic shock 17 . The pressor action of vasopressin in shock results from an overall increase in systemic vascular resistance (SVR), although markedly different responses occur between regional circulations. Blood flow is reduced to skin, skeletal muscle, small bowel and fat and increased to the heart and brain [32] [33] [34] [35] [36] [37] [38] . Blood flow is thereby diverted from non-critical to critical organ beds.
Exogenous vasopressin produces complex cardiac effects that are a mixture of direct and reflex actions 39 . In the isolated heart, low-dose vasopressin is a positive inotrope 40 . However in vivo, vasopressin decreases cardiac output in patients with normal hearts or mild heart failure, presumably as a reflex response to an increase in SVR 41, 42 . High-dose vasopressin decreases cardiac output by producing coronary vasoconstriction 43 . In an animal model of chronic heart failure, the vascular response to exogenous vasopressin was increased compared to controls despite the occurrence of normal endogenous levels 38 . This suggests that increased vascular responsiveness to endogenous vasopressin may contribute to the increase in SVR produced by heart failure.
Unlike adrenaline, vasopressin administration does not adversely affect renal blood flow in animal models of shock. Renal blood flow was increased in response to vasopressin infusion during haemorrhage 44 and severe heart failure 39 , and was unaffected by low-and high-dose bolus administration during CPR 32 . The actions of vasopressin on the splanchnic circulation may be affected by haemorrhage. Normally, portal venous pressures fall in response to reduced splanchnic blood flow. This is the mechanism by which vasopressin reduces variceal bleeding [45] [46] [47] . The magnitude of this response is reduced by haemorrhage 48 .
Mechanism of Action
The pressor actions of vasopressin are complex and incompletely understood. Vasopressin acts via specific renal (V-2) and vascular (V-1) receptors although vascular vasopressin receptors are not as well characterized as adrenergic receptors.
Vasopressin produces vasoconstriction in non-vital circulations by activation of V-1 receptors. In common with the α-adrenergic agonists, V-1 activation leads to increased levels of the second messengers inositol phosphate and diacylglycerol, which in turn activate voltage-gated calcium channels. This results in increased intracellular calcium levels, causing vasoconstriction 49 . How vasopressin produces vasoconstriction in some vascular beds and vasodilation at others is unclear, but the mechanism is related to endothelial nitric oxide (NO). Vasopressin has been shown to produce vasodilation in the renal 50 , pulmonary 37 , mesenteric 51, 52 and especially in the cerebral vascular beds [33] [34] [35] by stimulating endothelial NO release. Release of NO was shown to be mediated by V-1 receptors in the renal 50 and pulmonary circulations 37 . Conversely, the release of endothelial NO has been shown to inhibit the vasoconstrictor response to vasopressin in the coronary, cerebral and renal circulations 51 . This suggests that in these circulations, the basal, rather than the stimulated release of NO, accounts for the regional differences in the arterial response to vasopressin.
Although vasopressin has similar pressor actions to the catecholamines, it also has unique actions in reversing some of the pathologic vasodilatory processes that occur in advanced shock (which may be refractory to catecholamine vasopressors). There are two mechanisms by which this has been shown to occur (Figure 1 ). First, vasopressin inhibits ATPsensitive potassium channels (K ATP ) in vascular smooth muscle 53 . Tissue hypoxia or hypoperfusion due to hypovolaemia and septic shock has been shown to activate K ATP channels 54, 55 . Activation of K ATP channels produces cellular hyperpolarization which in turn inhibits voltage-gated calcium channels. Intracellular calcium levels fall, resulting in vasodilation 53 . Second, vasopressin inhibits the inflammatory cytokine interleukin 1-β 56 . Interleukin 1-β is released in response to trauma or infection 57, 58 and produces vasodilation by stimulating vascular endothelial NO production 56 . The mechanism by which vasopressin inhibits interleukin-1-β is unknown but it has been shown to be mediated by V-1 receptor activation.
In summary, the pressor actions of exogenously administered vasopressin in shock result not only from the restoration of impaired vasoconstrictor mechanisms (due to correction of relative vasopressin deficiency) but also from the inhibition of pathological vasodilator responses.
The antidiuretic properties of vasopressin result from an increase in the capillary permeability of the distal tubule and collecting duct of the nephron 59 . The vasopressin analogue desmopressin (DDAVP) is primarily a V-2 agonist, with only 0.05% of the pressor activity of arginine vasopressin 60 . Although vasopressin is antidiuretic, it has been shown to increase urine output during haemorrhage 44 , sepsis 31 and severe heart failure 39 . Possible explanations are that vasopressin may increase renal perfusion pressure secondary to increased systemic pressure and it may also increase glomerular filtration rate by selectively constricting the glomerular efferent arteriole 59 . Finally, renal sympathetic innervation is also involved in the modulation of the renal vascular response to vasopressin. In response to renal denervation, vasopressin produces a marked constrictor response 61 .
Pharmacokinetics of Vasopressin
In 10 healthy subjects, plasma levels of vasopressin were 3.3±0.36 pg/ml 5 . Based on a metabolic clearance rate of 500 ml/min, basal vasopressin production is estimated to be about 1.65 ng/min (0.8 mU/min) 5, 62 . Plasma vasopressin circulates as a free peptide (nonprotein bound), has a volume of distribution that approximates that of the extracellular fluid space (14 ml/kg) and has a plasma half-life of 24 minutes 63 . Metabolism is approximately two-thirds renal, the remainder mainly hepatic 62 . Most vasopressin filtered by the kidneys is reabsorbed by the tubules 5 . Urinary and metabolic clearance rates increase linearly (and proportionately) with increased vasopressin infusion rates 5, 30 and are reduced by chronic renal failure 64 and by cirrhosis 66 . There is no data on the effects of shock on the pharmacokinetics of vasopressin.
Synthetic Vasopressin Presentation
Vasopressin (Pitressin, Parke Davis Pty Ltd) is formulated as a sterile, aqueous solution, containing 20 U/1 ml ampoule of synthetic 8-arginine vasopressin in chlorbutol 0.5% preservative 65 .
VASOPRESSIN AND SHOCK: ANIMAL AND HUMAN STUDIES Vasopressin and Ventricular Fibrillation
Recent studies questioning the value of adrenaline during CPR have led to the search for alternative pressor agents. Standard and high-dose adrenaline did not lead to better short-term survival than placebo in one study 67 and high-dose adrenaline has not been shown to improve survival over standard dose [68] [69] [70] . In addition, the β-adrenergic properties of adrenaline may increase myocardial injury after successful resuscitation by worsening the imbalance between myocardial oxygen supply and demand 71 . Interest in the use of vasopressin as a therapy for ventricular fibrillation was triggered by the observation that vasopressin levels were significantly higher in resuscitated than in nonresuscitated patients undergoing CPR for out-of-hospital cardiac arrest 4 .
Pig Studies
During ventricular fibrillation and closed-chest CPR, vasopressin 0.8 U/kg produced significantly higher coronary perfusion pressure, myocardial and cerebral blood flow than did adrenaline 200 µg/kg 32 . In addition, vasopressin was longer acting than adrenaline: five minutes after adrenaline administration left ventricular and cerebral blood flow remained elevated 29% and 22% above baseline (respectively), for vasopressin the respective increases were 217% and 111%. Renal blood flow did not significantly differ between the groups, however vasopressin 0.8 U/kg lead to a greater reduction in nonvital organ flow (skeletal muscle, small intestine and fat) than did adrenaline 200 µg/kg.
The same research group demonstrated in two further studies that during prolonged cardiac arrest, vasopressin produced significantly better cardiovascular and neurological recovery than did adrenaline. In the first, 18 pigs were subjected to 15 minutes of cardiac arrest followed by three minutes of CPR. Either vasopressin 0.8 U/kg or adrenaline 200 µg/kg was then administered before defibrillation was attempted. Vasopressin produced greater increases in myocardial and cerebral blood flow than did adrenaline and return to spontaneous circulation was achieved in 8/9 vasopressin treated pigs but in only 1/9 of the adrenaline group (P<0.05) 72 . In the second study, ventricular fibrillation was induced in 17 pigs. After four minutes of cardiac arrest, basic CPR was performed for three minutes followed by a further 15 minutes of CPR-during which time the pigs received every five minutes either vasopressin (0.4, 0.4, 0.8 U/kg), adrenaline (45, 45 , 200 µg/kg) or placebo. Defibrillation was then attempted after 22 minutes in cardiac arrest. All of the six adrenaline and five placebo treated pigs died, whereas all six vasopressin pigs survived (P<0.05). Most impressively, these surviving pigs were essentially neurologically intact at 24 hours. They had only an unsteady gait, while MRI examination revealed no cerebral pathology 73 . Is there a potential synergistic action between vasopressin and adrenaline during CPR? In pigs undergoing CPR, a combination of vasopressin 0.3 U/kg and adrenaline 40 µg/kg resulted in a more rapid rise in coronary perfusion pressure than did either agent given alone 74 . However, two minutes after drug administration, coronary blood flow did not differ significantly between groups, while the cerebral blood flow in the vasopressin-alone group was more than twice that of both the adrenaline-alone group (0.76 vs 0.3 ml/min/g, P<0.01) and of the vasopressin + adrenaline group (0.76 vs 0.23 ml/min/g, P<0.01). The haemodynamic effects of vasopressin alone or in combination with adrenaline outlasted those of adrenaline alone, although the duration of action did not differ between the vasopressin-alone and vasopressin + adrenaline group. These results indicate that the addition of adrenaline to vasopressin did not confer any significant clinical benefit.
Vasopressin was also shown to be effective during hypothermic cardiac arrest 75 .
Intraosseous 76 and endobronchial 77 administration of vasopressin has been shown to be comparable to intravenous administration during CPR in terms of plasma levels, haemodynamic response and rate of successful resuscitation.
It should be noted that in all of the above studies, exogenous arginine vasopressin was administered. A potential limitation of these studies is that pigs possess lysine vasopressin receptors while humans have arginine vasopressin receptors. It is postulated therefore that the cardiovascular response to exogenous arginine vasopressin may be greater in humans than in pigs 73, 75 .
Human Studies
To date the human literature on the use of vasopressin for advanced cardiac life support (ACLS) is limited, but promising. In a randomized double-blind study of 40 patients receiving either adrenaline 1 mg or vasopressin 40 U for out-of-hospital ventricular fibrillation, twice as many patients in the vasopressin group (7 vs 14 patients) survived to hospital admission (NS). At 24 hours, four adrenaline-treated patients were alive vs 12 vasopressin-treated patients (P<0.02) 78 . In a study of 10 patients already deemed non-salvageable after prolonged conventional ACLS (mean duration 39.6±16.5 min), coronary perfusion pressure was measured five minutes after a bolus dose of adrenaline 1 mg, followed by vasopressin 1 U/kg. No improvement in coronary perfusion pressure occurred following adrenaline. However in four patients, vasopressin produced a mean increase in coronary perfusion pressure of 28.2 mmHg, with the peak increase occurring between 15 seconds and four minutes after drug administration 79 . The European Resuscitation Council is currently supporting a large Austrian study of vasopressin versus adrenaline for out-of-hospital cardiac arrest. This randomized, multicentre study of 1500 patients is due for completion later this year. Preliminary results from the first 450 cases have not revealed any adverse effects or complications associated with vasopressin use 80 . In the latest ACLS guidelines of the American Heart Association, vasopressin (40U IV as a single bolus) may be substituted for adrenaline in the treatment of cardiac arrest. The evidence-based classification of vasopressin is Class IIb (acceptable, with fair supporting evidence) 81 .
Vasopressin and Hypovolaemic Shock
The outcome from hypovolaemic cardiac arrest remains dismal [82] [83] [84] , leading to some trauma units advocating withholding treatment from patients who arrest from blunt trauma prior to arrival in hospital. CPR is unlikely to be effective in an exsanguinated patient and although adrenaline is advocated as part of ACLS for hypovolaemic cardiac arrest 85, 86 , its efficacy is unknown. In addition, after prolonged hypovolaemic shock, some patients will die from irreversible shock after initially responding to volume replacement and catecholamines. Irreversible shock ensues when there is a progressive reduction in vascular responsiveness to catecholamines, despite restoration of blood volume. Recent evidence suggests that vasopressin may improve survival from cardiac arrest occurring during hypovolaemia and may also reverse "irreversible" shock due to prolonged hypovolaemia.
Animal Studies
The effect of vasopressin on survival after cardiac arrest during hypovolaemic shock was studied in 18 anaesthetized pigs 87 . Thirty-five per cent of their blood volume was withdrawn and after 15 minutes VF was induced electrically. After four minutes of cardiac arrest, CPR was then performed for a further four minutes before a bolus dose of adrenaline 0.2 mg/kg (n=7), vasopressin 0.8 U/kg (n=7) or placebo (n=4) was administered. Defibrillation was attempted 2.5 minutes later, followed by repeat drug doses if unsuccessful. All vasopressin-treated pigs were successfully defibrillated, as were 6/7 adrenaline-treated pigs. None of the placebo group could be defibrillated. However, one hour later all of the adrenaline-and none of the vasopressin-treated pigs had died (P<0.01). Although mean arterial pressure and coronary, cerebral, and adrenal blood flow were significantly higher in the adrenaline group at five minutes, by 30 minutes they were all significantly lower than the vasopressin group. Renal blood flow was significantly higher in the vasopressin group at all times. Adrenaline-treated animals had a lower arterial and mixed venous pH during the entire post-resuscitation phase, possibly due to excess metabolism from β-adrenergic stimulation along with renal hypoperfusion. High-dose adrenaline may also cause cardiac failure following CPR from hypovolaemic shock by critically increasing myocardial oxygen demand above supply, consistent with the results from other experimental models of CPR 71, 88 . The effect of vasopressin on intractable shock was studied in seven dogs 17 . This was induced by draining blood from the animals into a reservoir until a mean arterial pressure (MAP) of 40 mmHg was reached. The height of the reservoir was then altered to maintain this MAP. After a variable period of time vasodilation occurred, indicated by the passive transfer of blood from the reservoir to the dogs. Severe hypotension persisted despite restoration of blood volume and noradrenaline infusion at 3 µg/kg/min. However, within five minutes of vasopressin infusion at 1 to 4 mU/kg/min, MAP increased from a mean of 39 to 128 mmHg (P<0.01) and remained above 90 mmHg for the 50-minute study period. As expected, vasopressin levels measured soon after the onset of hypotensive haemorrhage were markedly elevated (319±66 pg/ml), but had fallen to 29±9 pg/ml before vasopressin administration (P<0.01).
Human Experience
Vasopressin has been successfully used in two case reports of refractory hypotension due to haemorrhage 17 . The first patient had prolonged severe hypotension (systolic arterial pressure (SAP) 50 mmHg for >1 hour) from variceal bleeding that was refractory to volume replacement, high-dose noradrenaline and dopamine infusion. After 10 minutes of vasopressin infusion at 4µU/kg/min, the SAP was 160 mmHg and the catecholamines had been ceased. In the second case, prolonged severe hypotension occurred after a gastric bleed in a young adult with end-stage renal failure. This persisted despite transfusion to a CVP of 17 mmHg and noradrenaline infusion, however after 10 minutes of vasopressin infusion at 1 µU/kg/min the SAP rose from 70 to 130 mmHg. Both patients survived.
Vasopressin and Sepsis
The characteristic haemodynamic disturbance caused by septic shock is generalized vasodilation and myocardial depression. Acceptable mean arterial pressures may be restored by catecholamine vasopressors, but critical reductions in regional blood flow (especially splanchnic) may occur 89, 90 . However, in some patients with vasodilated septic shock, the pressor response to catecholamines may be markedly reduced 91, 92 while the response to vasopressin is markedly enhanced 31 . It was therefore hypothesized that a relative deficiency of endogenous vasopressin might contribute to this lack of vascular responsiveness 19 . Normally, sepsis is a potent stimulus for vasopressin release. In an animal model, massive endogenous vasopressin release occurred in response to infusion of E.coli 7 . Levels peaked within the first two hours, then declined, but remained well above baseline up to 12 hours later. The plasma vasopressin level produced was comparable to that seen in other severe shock states, such as hypotension due to haemorrhage. There is no animal data on the effect of prolonged septic shock on vasopressin levels. However, in a study of 19 humans with vasodilatory septic shock who were receiving catecholamines, plasma levels of vasopressin were significantly lower than in 12 patients who were in cardiogenic shock (3.1 vs 22.7 pg/ml, P<0.01) 17 . These levels were thought to be inappropriately low for the level of hypotension seen in these patients (mean systolic/diastolic pressures 92/52 mmHg). Vasopressin was then infused at 0.04 U/min in 10 patients. Within 15 minutes, the mean systolic arterial pressure increased to 146 mmHg (P<0.01) due to a 79% increase in systemic vascular resistance. In six patients, catecholamine therapy could be ceased. In these six patients, cessation of vasopressin infusion resulted in hypotension within a few minutes (SAP 126 to 83 mmHg, P<0.01). Reinstituting a lower-dose vasopressin infusion (0.01 U/min) resulted in a further sustained improvement in blood pressure (83 to 115 mmHg, P<0.01).
Vasopressin 0.04 U/min was compared with placebo in 10 patients with vasodilatory septic shock in a double-blind study (n=5 each group) 93 . Study criteria were septic patients who required catecholamine vasopressors to maintain a MAP of 70 mmHg despite a cardiac index of >2.5 l/min/m 2 and a PCWP of 12 mmHg. Vasopressin infusion resulted in an increase in systolic arterial pressure (98 to 125 mmHg, P<0.008) due to peripheral vasoconstriction (SVR 878 to 1190 dyn.s.cm -5 ). All of the vasopressin group were able to be completely weaned from catecholamines, and all patients survived the 24 hour study period. Two patients in the placebo group died from refractory hypotension (MAP <50 mmHg).
Vasopressin and Cardiopulmonary Bypass
Excessive vasodilation can occur soon after initiating cardiopulmonary bypass (CPB) due to the effects of haemodilution, cardioplegia and chronic ACEinhibitor therapy 21 . In a patient who developed hypotension during CPB that was refractory to boluses of phenylephrine and noradrenaline infusion, one unit of vasopressin effectively restored vascular tone 94 . Cardiopulmonary bypass induces an inflammatory response that causes similar haemodynamic disturbances to sepsis. Characteristic features are hypotension due to peripheral vasodilation, diminished vascular responsiveness to catecholamines and a high cardiac output. In a study of 145 general cardiac cases, post bypass vasodilatory hypotension occurred in 11 cases (8%). Plasma vasopressin levels were significantly lower in the vasodilated patients than in nine patients who had cardiogenic hypotension following CPB (12.0 vs 29.3 pg/ml, P<0.04) 21 . In a retrospective review from the same study, 26 heart transplant recipients and 16 patients on left ventricular assist devices received vasopressin (commencing at 0.1 U/min) for vascular support. Infusions were commenced on bypass up to several hours after weaning and were continued for up to six days. Vasopressin administration produced significant increases in MAP and vascular resistance along with significant reductions in noradrenaline support. The haemodynamic response to vasopressin was most pronounced in the most severely hypotensive group of patients. After catecholamine support had been successfully withdrawn, vasopressin was slowly tapered to 0.02 U/min, then discontinued.
Vasopressin can correct vasodilatory shock following CPB even in non-vasopressin deficient patients. In a randomized, controlled trial of 10 patients undergoing insertion of a left ventricular assist device who had post bypass vasodilatory shock, five patients received either vasopressin at 0.1 U/min or placebo 20 . Vasodilatory shock was defined as a MAP of <70 mmHg, a cardiac index of >2.5 l/min/m 2 and noradrenaline dependence. Vasopressin produced a rapid increase in mean arterial pressure (57±4 to 84±2, P<0.01) and SVR (813±113 to 1188± 87 dyn.s.cm -5 ). Within 15 minutes of commencing the vasopressin infusion, four patients could be completely weaned from noradrenaline. Although not significant, patients with low plasma vasopressin levels were more hypotensive and had a greater pressor response to vasopressin than patients with higher levels.
Administration of vasopressin (10 U followed by an infusion at 14, then 7 U/h) produced a marked haemodynamic improvement in a patient who had cardiogenic shock and pulmonary oedema after prolonged CPB for a double-valve procedure without affecting filling pressures 95 . Although the improvement in cardiac output may have been secondary to an increased coronary perfusion pressure, it is also possible that vasopressin produced a positive inotropic effect.
Adverse Effects of Vasopressin
Although there are a number of serious reported side-effects from vasopressin therapy for other clinical indications, there were no complications attributable to vasopressin in any of these studies reviewed, even after up to six days of vasopressin infusion.
There have been case reports of major complications produced by vasopressin in other clinical settings 65, 96 . Cardiac complications have lead to fatalities and include myocardial ischaemia, myocardial infarction, ventricular arrhythmias (including ventricular tachycardia and asystole) and severe hypertension. Severe gastrointestinal tract ischaemia leading to bowel necrosis has been reported as have hyponatraemia, anaphylaxis, bronchospasm, urticaria, angioedema and rashes. Peripheral vasoconstriction leading to cutaneous gangrene has been reported in five cases, in only one of whom was there evidence of extravasation. Venous thrombosis and local irritation of the injection site may also occur.
One explanation for the absence of side-effects from vasopressin use during shock may simply be that a relatively small number of patients have been studied. However, there are other possible explanations. The dose of vasopressin used in shock states was relatively low compared to that used in other indications. For example, the vasopressin doses typically used post CPB were 0.1 U/min, while the dose used for variceal bleeding is 0.1 to 0.4 U/min 97 . It is also possible that because shocked patients may have inappropriately low endogenous vasopressin levels, fewer side-effects might occur from exogenous vasopressin administration.
CONCLUSIONS
Vasopressin is an intriguing new therapy for a variety of vasodilatory shock states that promises to be a major advance in resuscitation.
Endogenous vasopressin release is an important pressor mechanism in the physiological response to shock, and inadequate vasopressin levels will exacerbate hypotension. Although vasopressin has some similar vascular actions to the catecholamines, it may uniquely also reverse some of the pathological vasodilatory processes produced by shock.
While there is relatively limited human data on the use of vasopressin in shock, the evidence available does confirm some of the promising findings from animal studies.
During ACLS for ventricular fibrillation, vasopressin produces more favourable and sustained blood flow diversion from non-critical to critical organ beds (especially brain) than does adrenaline, and may improve survival in humans. Should these findings be confirmed by large studies in progress, vasopressin may potentially supplant adrenaline as a first-line therapy.
Although human evidence is lacking, vasopressin may be a useful therapy for hypovolaemic cardiac arrest. There is also limited, though tantalizing evidence that vasopressin may reverse "irreversible" hypovolaemic shock.
Vasopressin is effective in reversing hypotension due to septic shock although there is as yet no data on outcome or on safety when compared with the use of the catecholamines.
Following cardiopulmonary bypass, vasodilation that is relatively refractory to catecholamines may be reversed by vasopressin. From the limited evidence available, vasopressin does not appear to produce adverse cardiac effects in this particularly vulnerable group of patients. Further studies are needed on how vasopressin might best be used for this indication. As well as further clinical studies on efficacy and safety, there is a need for pharmacodynamic and pharmacokinetic information on the use of vasopressin in shock.
